Obermatt

Curatis Holding

SWX:CURN · CH1330780979
PharmaceuticalsX-Small

360

70
Profit price82
Cash yield98
Price/Sales93
EV / Gross Profit11
Price/Book88
Return on Capital50
Return on Equity53
EBIT Margin21
Gross Profitability21

Cash truth not applicable for financial companies.

Sales growth100
Profit growth34
Reinvestment54
Price momentum94
Debt load57
Debt serviceability45
Liquidity10
Analyst ratings
Expectations trend
Market mood12
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Curatis Holding clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeSWX
ISINCH1330780979
Last UpdateApr 2, 2026
Themes
OphthalmologyPain ManagementNeurologyOncologyCentral Nervous System

Description

Analysis

Middle-of-the-road

Curatis Holding AG is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 13/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
70
2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
Price/Earnings
78
Price/Book
88
Dividend Yield
98
Value (overall)
98

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Curatis Holding with its peers
GlaxoSmithKline Pharmaceuticals
NSI:GLAXO
53
CountryUK
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
ALK-Abelló
CPH:ALK B
83
CountryDenmark
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
BioVersys
SWX:BIOV
11
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Sol-Gel Technologies
NAQ:SLGL
36
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Bayer
GER:BAYN
15
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Almirall
MCE:ALM
74
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →